N-(4-Fluorophenyl)formamide

Base Information

• Chemical Name: N-(4-Fluorophenyl)formamide
• CAS No.: 459-25-6
• Molecular Formula: C7H6 F N O
• Molecular Weight: 139.129
• Hs Code.: 2924297099
• European Community (EC) Number: 653-266-0
• NSC Number: 40549
• DSSTox Substance ID: DTXSID20285115
• Nikkaji Number: J796.589C
• Wikidata: Q82020369
• Mol file: 459-25-6.mol

Synonyms:N-(4-Fluorophenyl)formamide;459-25-6;1-Fluoro-4-formamidobenzene;4-fluorophenylformamide;N-(4-Fluorophenyl)formamidine;p-Fluor-formanilid;NSC40549;4'-Fluoroformanilide;SCHEMBL90440;N-(4-Fluoro-phenyl)-formamide;SCHEMBL21039201;DTXSID20285115;Formamide, N-(4-fluorophenyl)-;GEO-03008;MFCD00021019;NSC-40549;AKOS006349267;N-Formyl derivative of p-fluoroaniline;AS-59113;F0546;EN300-171500;F21300

Chemical Property of N-(4-Fluorophenyl)formamide

Chemical Property:

• Vapor Pressure: 0.00424mmHg at 25°C
• Melting Point: 67 °C
• Boiling Point: 278.5°Cat760mmHg
• Flash Point: 122.3°C
• PSA: 29.10000
• Density: 1.26g/cm³
• LogP: 2.10290
• Storage Temp.: 2-8°C
• XLogP3: 1.3
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 1
• Exact Mass: 139.043341977
• Heavy Atom Count: 10
• Complexity: 110

Purity/Quality:

97% ^*data from raw suppliers

N-(4-Fluorophenyl)formamide ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC(=CC=C1NC=O)F

Technology Process of N-(4-Fluorophenyl)formamide

There total 33 articles about N-(4-Fluorophenyl)formamide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 99.0%

carbon dioxide (124-38-9,18923-20-1) + 4-fluoroaniline (371-40-4) → N-(4-fluorophenyl)formamide (459-25-6)

Guidance literature:

With phenylsilane; C₁₄H₂₄N₄Si*HI; In benzene-d6; at 60 ℃; Inert atmosphere; Schlenk technique;

DOI:10.1021/acscatal.0c03795

Reference yield: 99.0%

formic acid (64-18-6) + 4-fluoroaniline (371-40-4) → N-(4-fluorophenyl)formamide (459-25-6)

Guidance literature:

With CuO impregnated on mesoporous Fe₃O₄ nanocomposite; at 25 ℃;

DOI:10.1002/ejoc.202100872

Reference yield: 97.0%

Methyl formate (107-31-3) + 4-fluoroaniline (371-40-4) → N-(4-fluorophenyl)formamide (459-25-6)

Guidance literature:

With calcium(II) bis(trifluoromethanesulfonyl)imide; In neat (no solvent); at 115 ℃; for 1h; Reagent/catalyst; Microwave irradiation; Sealed tube;

DOI:10.1002/ejoc.201600226

upstream raw materials:

formic acid

4-fluoroaniline

Methyl formate

formyl acetic anhydride

Downstream raw materials:

4-fluoro-N,N-dimethylaniline

4-fluoro-N-methylaniline

4-fluoroaniline

C₆H₄FN(CHO)SCFCl₂

Refernces

Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma

10.1016/j.bmc.2008.07.015

The research focuses on the design, synthesis, and preliminary biological evaluation of acridine compounds for a combined targeted chemo-radionuclide therapy approach to treat melanoma. The study exploits the structural similarity of these compounds to benzamides, which are known to have a specific affinity for melanin. The experiments involved the preparation of iodo-acridone and acridine carboxamides, which were evaluated for their in vitro cytotoxic properties and then radioiodinated with [125I]NaI for high specific activity. Biodistribution studies in B16F0 murine melanoma tumor-bearing mice were conducted to assess the tumor concentrations and in vivo kinetic profiles of the compounds. The main reactants used in the synthesis include various iodo-acridone and acridine carboxamide derivatives, along with reagents like [125I]NaI for radioiodination. Analyses included cytotoxicity assays, partition coefficient measurements, in vitro binding to melanin, and in vivo biodistribution studies to evaluate the compounds' affinity for melanoma tumors and their elimination rates. The research aimed to identify lead candidates for use in radionuclide therapy and/or chemotherapy of melanoma, with a focus on compounds that demonstrated high, long-lasting tumor concentrations and favorable kinetic profiles for targeted radionuclide therapy.